期刊文献+

高效液相色谱法测定细胞核内多柔比星浓度 被引量:2

Determination of Doxorubicin Concentrations in MDR Cancer Cell Nuclei by HPLC
下载PDF
导出
摘要 目的建立高效液相色谱-荧光测定法测定K562/DOX(doxorubicin—resistant K562 cells,耐多柔比星K562细胞)细胞核多柔比星浓度,方法分离K562/DOX细胞核,多柔比星浓度测定采用Diamond C18色谱柱,甲醇-水-醋酸(50:50:0.25)为流动相,流速1.0mL·min^-1,柱温35℃,荧光检测,激发波长497nm,发射波长555nm,以盐酸柔红霉素为内标、结果细胞核中多柔比星浓度在5.0~5000.0μg·L^-1内呈良好线性关系,r=0.99997加样回收率为98.55%~100.84%(RSD1.77%~3.27%),日内和日间精密度均〈15%,最低检测浓度为5.0μg·L^-1.结论该方法简单、方便,检测限低,精确度和回收率良好,可用于多药耐药肿瘤细胞内多柔比星浓度的胞内动力学研究. OBJECTIVE To develop a method using HPLC with fluorescence detector for determining the Doxorubicin concentrations in K562/DOX cell nuclei. METHODS Nuclei were isolated by modifying a method that employed isotonic conditions and detergent lysis. The mobile phase consisted of methanol-water- acetic acid (50: 50: 0. 25). The flow rate of the mobile phase was set at 1.0 mL · min^-1, and the eluent was monitored at an excitation wavelength of 497 nm and an emission wavelength of 555 nm. Calibration curves were computed using the area ratio of doxorubicin to daunorubicin (the internal standard). RESULTS The linear calibration curve was observed in the concentration range of 5.0 - 1 000 μg · L^-1. The lower limit of quantification was 5.0 μg· L^-1. The spotting recoveries were 98.55% - 100. 84%. The inter-and intra- day precision (RSD) was below 15%. CONCLUSION The method was proved to be convenient,sensitive and rapid,and suitable for the determination of doxorubicin in nuclei.
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第16期1264-1267,共4页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(30572270) 浙江省自然科学基金项目(Y207259)
关键词 高效液相色谱法 多柔比星 细胞核 K562/DOX细胞 HPLC doxorubicin nuclei K562/DOX cell
  • 相关文献

参考文献11

  • 1ROBERT J,JARRY C. Muhidrug resistance reversal agents[ J]. J Med Chem,2003,46(23) :4805-4817. 被引量:1
  • 2KRISHNA R, MAYER L D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[ J]. Eur J Pharm Sci,2000,11 (4) :265-283. 被引量:1
  • 3XIONG X B, HUANG Y, LU W L, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic [ J ]. J Controlled Release,2005,107 (2) :262-275. 被引量:1
  • 4WONG H L, RAUTH A M, BENDAYAN R,et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells [ J ]. Pharm Res ,2006,23 (7) : 1574-1585. 被引量:1
  • 5XIONGG CHENY ARRIAGAEA.Measuring the doxorubicin content of single nuclei by micellar electrokinetic capillary chromatography with laser-induced fluorescence detection .分析化学,2005,77(11):3488-3493. 被引量:1
  • 6ALAKHOV V Y, MOSKALEVA E Y, BATRAKOVA E V, et al. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer [ J ]. Bioconjug Chem, 1996,7(2) :209-216. 被引量:1
  • 7ALAKHOV V, KLINSKI E, LI S, et al. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials [ J ]. Colloids and Surfaces B : Biointerfaces, 1999,16 ( 1-4 ) : 113 -134. 被引量:1
  • 8LAHIRI D K, GE Y. Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue [ J ]. Brain Res Brain Res Protoc,2000, 5 (3) :257-265. 被引量:1
  • 9邹豪,蒋雪涛,马伯良,郭涛,隋因,周俭平.RP-HPLC荧光检测法同时测定血浆中的盐酸维拉帕米和活性代谢物去甲维拉帕米的浓度[J].中国药学杂志,2001,36(8):537-539. 被引量:7
  • 10REN Y, WEI D. Quantification intracellular levels of oligodeoxynucleotide-doxorubicin conjugate in human carcinoma ceils in situ [ J ]. J Pharm Biomed Anal,2004,36 (2) :387-391. 被引量:1

二级参考文献9

共引文献12

同被引文献18

  • 1Greiner A, Wendorff J H, Yarin A L, Zussman E. Appl. Microbiol. Biotechnol., 2006,71(4): 387-393. 被引量:1
  • 2Abidian M R, Kim D H, Martin D C. Advanced Materials, 2006, 18(4) : 405-409. 被引量:1
  • 3Priya A R S, Subramania A, Jung Y S , Kim K J. Langmuir, 2008,24(17):9816-9819. 被引量:1
  • 4Liu Z Y, Kang X J, Fang F. Microchimica Acta, 2010,168(1-2) : 59-64. 被引量:1
  • 5Fang F, Kang X J, Liu Z Y, Ma Y Q, Gu Z Z. Chinese Chemical Letters, 2009,20(12) : 1491 -1494. 被引量:1
  • 6Qi D J, Kang X J, Chen L Q, Zhang Y Y, Wei H M, Gu Z Z. Anal. Bioanal. Chem. , 2008, 390(3) : 929-938. 被引量:1
  • 7赖斌斌 陈宝安 程坚 高峰 许文林 丁家华 高冲 孙新臣 李国宏 陈文姬 刘莉洁 李小毛 王雪梅.中国实验血液学杂志,2009,17(2):245-351. 被引量:1
  • 8A1-Abd A M, Kim N H, Song S C, Lee S J, Kuh H J. Archives of Pharmacal Research, 2009,4(32) : 605-611. 被引量:1
  • 9Hu T, Le Q H, Wu Z Y, Wu W. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43(1) : 263-269. 被引量:1
  • 10Veronese F M, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R Bioconjugate Chemistry, 2005, 16(4) : 775-784. 被引量:1

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部